SAROCLADIUM STRICTUM injection, solution ALTERNARIA ALTERNATA injection, solution ASPERGILLUS FUMIGATUS injection, solution A

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

即購入

ダウンロード 製品の特徴 (SPC)
10-03-2023

有効成分:

SAROCLADIUM STRICTUM (UNII: 3F36V0451W) (SAROCLADIUM STRICTUM - UNII:3F36V0451W)

から入手可能:

ALK-Abello, Inc.

投与経路:

PERCUTANEOUS

適応症:

These products are for diagnostic use only. Diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. By measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. For extracts standardized in AU and BAU, see individual directions for use. Allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. Patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed WARNING statement and ADVERSE REACTIONS ). The physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. Patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

製品概要:

For scratch and prick testing: 5 mL dropper applicator vials in 50% v/v glycerin or 10mL stoppered vial in 50% v/v glycerin. Available individually and in a complete set of the most common allergens. Available in either Protein Nitrogen Units (PNU/mL) or weight to volume (w/v). For intracutaneous testing: 5 mL sterile vials, aqueous based, individually and in a complete set of the most common allergens. Available in either Protein Nitrogen Units (PNU/mL) or weight to volume (w/v). Histatrol ® Positive skin test control - histamine. 1 mg/mL and 0.1 mg/mL histamine base. See Product Catalog for specific diagnostic concentrations available.

認証ステータス:

Biologic Licensing Application

製品の特徴

                                SAROCLADIUM STRICTUM- SAROCLADIUM STRICTUM INJECTION, SOLUTION
ALTERNARIA ALTERNATA- ALTERNARIA ALTERNATA INJECTION, SOLUTION
ASPERGILLUS FUMIGATUS- ASPERGILLUS FUMIGATUS INJECTION, SOLUTION
AUREOBASIDIUM PULLULANS- AUREOBASIDIUM PULLULANS VAR. PULLUTANS
INJECTION,
SOLUTION
BIPOLARIS SOROKINIANA- COCHLIOBOLUS SATIVUS INJECTION, SOLUTION
BOTRYTIS CINEREA- BOTRYTIS CINEREA INJECTION, SOLUTION
CANDIDA ALBICANS- CANDIDA ALBICANS INJECTION, SOLUTION
CLADOSPORIUM CLADOSPORIOIDES- CLADOSPORIUM CLADOSPORIOIDES INJECTION,
SOLUTION
EPICOCCUM NIGRUM- EPICOCCUM NIGRUM INJECTION, SOLUTION
GIBBERELLA PULICARIS- GIBBERELLA ZEAE INJECTION, SOLUTION
MUCOR PLUMBEUS- MUCOR PLUMBEUS INJECTION, SOLUTION
PENICILLIUM NOTATUM- PENICILLIUM CHRYSOGENUM VAR. CHRYSOGENUM
INJECTION,
SOLUTION
RHODOTORULA MUCILAGINOSA- RHODOTORULA MUCILAGINOSA INJECTION, SOLUTION
SACCHAROMYCES CEREVISIAE- SACCHAROMYCES CEREVISIAE INJECTION, SOLUTION
TRICHOPHYTON MENTAGROPHYTES- TRICHOPHYTON MENTAGROPHYTES INJECTION,
SOLUTION
ALK-ABELLO, INC.
----------
DIAGNOSTIC MOLD
ALLERGENIC EXTRACTS,
FOR DIAGNOSTIC USE ONLY
DIRECTIONS FOR USE
WARNING
This product is intended for use by physicians who are experienced in
the
administration of allergenic extracts and the emergency care of
anaphylaxis, or for
use under the guidance of an allergy specialist.
As with all allergenic extracts, severe systemic reactions may occur.
In certain
individuals these life-threatening reactions may result in death.
Fatalities associated
with skin testing have been reported. Patients should be observed for
at least 20 -
30 minutes following testing. Emergency measures and adequately
trained
personnel should be immediately available in the event of a
life-threatening reaction.
Patients with unstable asthma or steroid dependent asthmatics and
patients with
underlying cardiovascular disease are at greater risk to a fatal
outcome from a
systemic allergic reaction.
Sensitive patients may experience severe anaphlactic reactions
resulting in
respiratory obstruction, shock, coma and/or death. Adver
                                
                                完全なドキュメントを読む
                                
                            

この製品に関連するアラートを検索